The objective of this study was to produce antiidiotypic antibodies with bovine somatotropin (bST)-like activity by active immunization of lactating cows and to determine their effects on milk yield. Several monoclonal antibodies against bST were evaluated for their interaction with bST in a rat growth bioassay. Two bST-agonist monoclonal antibodies ( 1 and 2), and two bST-antagonist monoclonal antibodies ( 3 and 4 ) were selected. Cows were immunized with immunoglobulin G as a control ( n = 12) or with one of the four anti-bST monoclonal antibodies (1, 2, 3, 4; n = 12) on d 3, 24, 45, 66, 87, 108, 129, and 150 of lactation. From wk 3 of lactation, all cows immunized with each of the four anti-bST monoclonal antibodies developed anti-idiotypes until wk 30 of lactation. Total lactation yields were not different among monoclonal antibodies 2, 3, and 4 and control cows (9299, 9321, 9733, and 9415 kg, respectively). However, cows immunized with anti-bST monoclonal antibody 1 had reduced lactation yield compared with cows on other treatments (8136 kg). Daily milk yield of cows immunized with monoclonal antibody 1 was decreased from wk 9 of lactation [36.2 vs. 40.9 kg/d (control)] until the end of lactation, concomitantly with decreased bST concentration from wk 9 of lactation. Cows immunized with anti-bST monoclonal antibody 4 had increased milk yield compared with that of controls during wk 3 to 6 and wk 18 to 21 of lactation. Therefore, anti-idiotypes directed against anti-bST 1 had bST-antagonistic effects on lactation performance; anti-idiotypes against anti-bST 4 transiently increased milk yield. ( Key words: bovine somatotropin, milk yield, monoclonal antibody, anti-idiotypes) Abbreviation key: GHBP = growth hormone binding protein, MoAB = monoclonal antibody, pbST = pituitary bST, rbST = recombinant bST, ST = somatotropin.
INTRODUCTION
Anti-idiotypic antibodies have been widely investigated for their ability to mimic the biological function of their original antigen as described for insulin (34) , thyroid-stimulating hormone ( 7 ) , LH (31) , prolactin ( 1 ) , FSH (38) , and estradiol-17b (27) . Anti-idiotypic antibodies may, therefore, be considered for use as long-acting bST mimics to enhance milk yield of cows. Human somatotropin ( ST) antiidiotypic antibodies inhibited human ST binding to rat liver microsomes and growth hormone binding protein ( GHBP) in vitro (17) . Rat ST anti-idiotypic antibodies, induced in sheep and mice, mimicked ST by inhibiting 125 I-ovine ST binding to sheep liver membranes (19) . These anti-idiotypic antibodies also increased weight gain of hypophysectomized rats, which suggested their ability to stimulate ST-like biological effects, although IGF-I concentrations were not affected (11) . We have previously immunized lactating cows with polyclonal rabbit anti-bST and induced anti-idiotypic antibodies with substantial increases in circulating immunoreactive bST concentrations, but no effect was observed on milk yield (33) . Schalla et al. ( 3 3 ) hypothesized that biological effects were not observed because the anti-bST was polyclonal and insufficiently specific for the active site of bST. The present study, therefore, sought to determine whether bST-mimicking anti-idiotypic antibodies could sustain a milk yield response. To test this hypothesis, mouse monoclonal antibodies ( MoAb) against bST were isolated, and their bioactivities were determined in a rat growth bioassay. To evaluate the effects of anti-idiotypic antibodies, some of these anti-bST MoAb were used to immunize lactating cows. The bST-like effects in the immunized animals were evaluated by determining milk yield and by measuring concentrations of circulating immunoreactive bST and IGF-I.
MATERIALS AND METHODS

Production of Mouse Anti-bST MoAb
Twelve BALB/C mice (Charles River, St. Constant, QC, Canada) at 3-wk intervals were immunized by intraperitoneal injection of 20 mg of recombinant bST ( rbST; American Cyanamid Co., Princeton, NJ) in Freund's incomplete adjuvant (Sigma Chemical Co., St. Louis, MO) until suitable antibody titers were obtained (1:3200 to 1:12,800 at 50% binding). Antibody titers were based upon binding to bST in a standard ELISA using alkaline phosphatase-labeled goat anti-mouse IgG (Sigma Chemical Co.). Spleen lymphocytes of the bST-immunized mice were fused with SP2/O mouse myeloma cells (using standard techniques) to produce hybridomas (20) . Hybridomas were grown in medium RPMI 1640 (Gibco Laboratories, Grand Island, NY) supplemented with 1% sodium pyruvate, 1% glutamine, 1% nonessential amino acids (Gibco Laboratories), and 10% heatinactivated fetal calf serum (Immunocorp, Montreal, QC, Canada). The anti-bST positive hybridomas were detected by ELISA and subcloned by limiting dilution (20) . The avidity of 50 MoAb from four mice was determined using a chaotropic ion elution ELISA ( 4 ) . The anti-bST MoAb remaining bound to bST after treatment with various molarities (0, 0.25, 0.5, 1, 2, and 4 M) of thiocyanate ion was quantitated, and an avidity index was calculated from the concentration of thiocyanate that reduced bound antibody by 50% ( 4 ) . Thirteen of the highest avidity MoAb were selected, purified using protein A membrane affinity chromatography (Amicon Division, W. R. Grace & Co., Beverly, MA), and concentrated in an ultrafiltration cell (model 8050; Amicon Division, W. R. Grace & Co.) using an ultrafiltration membrane with a molecular mass exclusion greater than 10,000 Da (Diaflo ultrafilters PM10; Amicon Division, W. R. Grace & Co.). A total of 75 mg of each anti-bST MoAb was purified and stored at -20°C. All MoAb were IgG1 (Sigma immunotype kit; Sigma Chemical Co.).
Bioactivity of Anti-bST MoAb
The interaction of the 13 anti-bST MoAb with bST was tested in a rat growth bioassay. This bioassay used hypophysectomized male Sprague-Dawley rats (21 d of age; Charles River), which received daily s.c. injections of 1 ) one of 13 different MoAb against bST (500 mg/d) complexed with bST (10 mg/d) ( n = 8), 2 ) bST alone (10 mg/d) ( n = 8), or 3 ) saline ( n = 8 ) over 5 d. The anti-bST MoAb and bST were incubated in 0.9% saline at 20°C for 30 min prior to injection. Body weight gain was determined daily for 10 d from initiation of treatments. The potency of anti-bST MoAb was determined as the mean ratio of the slope of the growth curve of each MoAb + bST group with the slope for bST alone. The bST growth curve was considered the reference and had a ratio of 1. Therefore, MoAbs with ratio values above or below 1 had bSTenhancing or -inhibiting effects, respectively. Two of the MoAb with the highest bST potentiating potency (agonist MoAb 1 and MoAb 2 ) and the two most potent inhibitors (antagonist MoAb 3 and MoAb 4 ) were used as antigens for active immunization of lactating cows. These four MoAb were tested individually in Western blots with two different sources of bST: rbST, and pituitary bST ( pbST; supplied by A. F. Parlow, Pituitary Hormones and Antisera Center, Torrance, CA). The Western blots were performed as previously described ( 3 ) with the following exceptions. Electrophoresis was with either 100 ml of rbST or pbST at 0.2 mg/ml in 125 mM Tris·HCl, 10% 2-mercaptoethanol, 4% SDS, and 20% glycerol (pH 6.8; BioRad, Richmond, CA). Prestained low range molecular mass standards were used (BioRad). After Western transfer and blocking, the nitrocellulose membranes were incubated in a 16-lane mini-blotter (BioRad) with 150 ml of supernatant from hybridomas of each anti-bST MoAb (MoAb 1, 2, 3, and 4). Membranes were then incubated with goat antimouse IgG alkaline phosphatase conjugate (1:1000 in PBS). Antibody binding was detected with naphthol AS-MX phosphate, fast red substrate (Sigma Chemical Co.).
Production of bST Anti-Idiotypes in Lactating Cows
Cows. Sixty multiparous Holstein cows were randomly assigned at calving to one of the five treatments: immunization with normal mouse IgG (Sigma Chemical Co.) (control; n = 12) or immunization with one of the four anti-bST MoAb ( n = 12). Initiation of treatment occurred within a 6-mo time interval. All cows were housed in a tie-stall barn with artificial lighting from 0500 to 2300 h. They were milked twice daily in a parlor at 0500 and 1600 h; milk weights were recorded at each milking. Cows were fed a totally mixed ration of 50% forage and 50% concentrate (mixed hay, alfalfa haylage, corn silage, high moisture grain corn, and soybean meal) for ad libitum intake. Feed intake and BW were recorded daily and weekly, respectively, for each cow.
Treatments. Primary immunization was given on d 3 after calving followed by seven immunizations at 3, 6, 9, 12, 15, 18, and 21 wk of lactation. Primary and repeated immunizations used Freund's complete and incomplete adjuvants (Sigma Chemical Co.), respectively, emulsified (1:1, vol/vol) with 800 mg of anti-bST MoAb (or IgG) plus 1 mg of Quillaha saponin (Sigma Chemical Co.). The injection volume was 2 ml administered i.m. into the gluteal muscle. Blood samples were collected twice weekly throughout the lactation period (43 wk). Blood was allowed to clot for 3 h at 4°C and was centrifuged at 1200 × g for 20 min. Serum was decanted and stored at -20°C. Milk collected weekly as separate a.m. and p.m. samples was analyzed for milk fat, protein, and lactose concentrations using an infrared spectrometer (Multispec Inc., Wheldrake, York, United Kingdom). Estimates of 3.5% FCM were calculated from each daily milk yield using the corresponding weekly estimate of milk fat concentration. The equation used was: (0.432 × kilograms of milk) + (16.2 × kilograms of fat) as previously described (37) . Total milk production was based on 305 d of lactation.
Determination of bST anti-idiotypic antibody titers. The presence of bST-like antibodies (antiidiotypes) was determined by indirect homologous ELISA. This method relies on the presence of bST or bST-mimicking antibody in serum to inhibit binding of a fixed quantity of homologous anti-bST MoAb to bST-coated wells. Quantification of the anti-idiotype was relative to bST as a reference in each assay. Briefly, 50 ml of bST at 5 mg/ml in 0.05 M carbonate buffer (pH 9.6) was dispensed into microtiter plates (Immulon 2; Dynatech Laboratories, Chantilly, VA) and incubated at 4°C overnight. After plates were washed with PBS (pH 7.4) containing 0.05% Tween-20 (Sigma Chemical Co.), 100 ml of blocking buffer (PBS-3% Tween-20) was incubated in each well at room temperature (22°C ) for 1 h. The plates were then washed several times with washing buffer, and 50 ml of the test cow serum [diluted 1:10 (vol/vol) in wash buffer] was incubated with 50 ml of the appropriate anti-bST MoAb (100 mg/ml in wash buffer) in each well for 2 h at room temperature (22°C). For the bST standard curve, 50 ml of different concentrations of bST (0.63 to 100 ng/ml) was substituted for the test serum (35) . Unimmunized cow serum was used as a negative control (minimal absorbance), and the MoAb alone was used as a positive control (maximal absorbance). These two controls were used as references between plates. The plates were washed again, and 50 ml of alkaline phosphatase-conjugated sheep anti-mouse IgG (Sigma Chemical Co.) diluted 1:2000 (vol/vol) in washing buffer was added. After incubation for 2 h at room temperature (22°C ) and washing, 100 ml of p-nitrophenylphosphatediethanolamine substrate (Kirkegaard and Perry Laboratories, Gaithersburg, MD) was added and incubated at 37°C for 30 min. The absorbance at 405 nm was determined with an ELISA reader (Titertek Multiskan Plus, Flow Laboratories, Mississauga, ON, Canada). Absorbance measurement of the test cow serum was subtracted from the absorbance of the negative control and then converted to its equivalent bST concentration according to the bST standard curve.
Milk yield, serum bST, and IGF-I measurements. Serum bST and IGF-I concentrations were measured by radioimmunoassay as previously described ( 3 3 ) except that the anti-IGF-I was obtained from GroPep (Adelaide, Australia) and was used at a dilution of 1:80,000 (vol/vol). The detection limit was between 0.02 and 8.0 ng/ml for the bST radioimmunoassay. Intraassay and interassay coefficients of variation for the bST radioimmunoassay were 7.4 and 13.5%, respectively. Intraassay and interassay coefficients of variation for the IGF-I radioimmunoassay were 6.3 and 8.0%, respectively.
Statistical analysis. In the rat growth bioassay, daily cumulative weight gain was compared between treatments for each treatment day with the general linear model procedure of SAS ( 3 2 ) using the pretreatment weight as a covariate. Concentrations of anti-idiotypes, bST, and IGF-I and yields of FCM were analyzed by immunization period ( 3 wk intervals) in which treatment comparisons were made by ANOVA for repeated measurements (32) . Total lactation FCM yields were compared among treatments using the general linear models procedure ( 3 2 ) with FCM yield of the previous lactation as the covariate.
RESULTS
Interaction of Anti-bST MoAb with bST in Hypophysectomized Rats
Avidity measurements were made for 50 anti-bST MoAb to evaluate binding to bST in the chaotropic ion elution ELISA. Their avidity indexes ranged from 0.67 to 2.8 M. Thirteen anti-bST MoAb with the highest avidities for bST ranging from 1.7 to 2.8 M were selected to be further evaluated in the rat growth assay. Mouse anti-bST MoAb (13 different) when complexed with bST either enhanced ( P < 0.05), decreased ( P < 0.05), or had no effect ( P > 0.05) on the growth of hypophysectomized rats relative to bST alone. The effects of the two most potent agonist and antagonist antibodies are illustrated in Figure 1 . These four anti-bST MoAb were all confirmed to be specific for bST by Western blotting with two different sources of bST (rbST and pbST; data not shown). Without bST, the hypophysectomized rats did not grow. The increased weight of rats treated with MoAb 1 and 2 was sustained after the end of treatment and remained higher than the bSTtreated rats until the end of the experiment ( 5 d posttreatment; data not shown). From d 1 of treatment until the end of treatment, MoAb 1-and 2-treated groups had significantly higher weight gain than bST alone ( P < 0.05). The MoAb 3-and 4-treated groups differed from the bST-treated group on d 3 and 4 ( P < 0.05) with a tendency for differences on d 2 and 5 of treatment ( P < 0.1). Rats treated with bST plus anti-bST MoAb 1 and 2 grew 1.40 and 1.35 times more, respectively, than did rats treated with bST alone. In contrast, bST plus MoAb 3 and 4 were associated, respectively, with weight gains of 0.74 and 0.75 times that of bST alone. There was a tendency for MoAb 1 and 2 (agonists) to have higher avidity for bST (2.8 and 2.5 M, respectively) than did those of the antagonist MoAb 3 and 4 (2.2 and 2.0 M, respectively; P < 0.1). These four anti-bST MoAb were chosen as antigens for the production of antiidiotypes in cows.
Effect of bST Anti-Idiotypes in Lactating Cows
All 60 cows developed antibodies to mouse IgG by the second immunization, which demonstrated that the cows were responding to the immunization (data not shown). Cows immunized with mouse IgG (control) did not develop bST-like activity above that expected from endogenous bST when tested in competition with any of the four MoAb (Figure 2a) . From the second immunization (or wk 3 of lactation), all cows immunized against one of the four anti-bST MoAb developed anti-idiotypes with crossreacting bST-equivalents higher than controls ( P < 0.001; Figure 2a ). In cows immunized with MoAb 2, 3, and 4, this difference was observed until wk 30 of lactation, which corresponded to 9 wk after the last immunization ( P < 0.05). Cows immunized with MoAb 1 had higher bST-equivalent concentrations until the end of lactation (wk 33 of lactation) ( P < 0.001). Cows immunized with MoAb 4 had lower bSTequivalent concentrations than did cows immunized with MoAb 1 from the sixth immunization (wk 15 of lactation) until the end of lactation (wk 33 of lactation) ( P < 0.05).
Milk yields for the entire lactation period studied are presented in Table 1 . There was no difference in total milk yield among cows immunized with MoAb 2, 3 or 4 and control cows, but cows immunized with MoAb 1 had reduced milk yield compared with control cows ( P < 0.05). There was also no correlation between the MoAb avidity index and FCM ( P > 0.05). The milk yields according to each immunization period are shown in Figure 2d . Cows immunized with MoAb 4 had increased milk yield ( P < 0.05) compared with control cows during the periods of wk 3 to 6 and wk 18 to 21 of lactation. In contrast, milk yield was depressed following the third immunization with MoAb 1 (wk 6 of lactation) and was less than that of controls throughout lactation (until wk 33 of lactation; P < 0.05). Cows immunized with anti-bST MoAb 2 or 3 had similar milk yields to those of the controls throughout the 33 wk of lactation ( P > 0.05). Figure 2a represents the mean serum bST anti-idiotypes (expressed as the equivalent of bST ± SEM). From the second immunization (wk 3 of lactation), all anti-bST MoAb-immunized groups developed anti-idiotypes with bST-equivalent concentrations higher than the control cows ( P < 0.05). Figure 2b represents the concurrent changes in mean serum concentrations of immunoactive bST ( ±SEM). Immunoactive bST concentrations were lower in MoAb 1-immunized cows than in control cows from the fourth immunization until the end of the lactation (wk 33 of lactation; P < 0.05). Figure 2c represents changes in mean serum IGF-I concentrations ( ±SEM). Cows immunized with MoAb 4 had decreased concentrations of IGF-I compared with control cows from wk 15 to 27 of lactation ( P < 0.05). Figure 2d represents the mean FCM yields ( ±SEM). Cows immunized with anti-bST MoAb 4 had increased milk yield ( P < 0.05) compared with control cows during wk 3 to 6 and wk 18 to 21 of lactation. In anti-bST MoAb 1, milk yield decreased following the third immunization and remained less than controls throughout lactation (until wk 33 of lactation; P < 0.05).
Immunoactive bST concentrations measured by polyclonal radioimmunoassay decreased during lactation and were lower in cows immunized with MoAb 1 than in control cows from the fourth immunization (wk 9 of lactation) until the end of the lactation (wk 33 of lactation; P < 0.05; Figure 2b ). Cows immunized with MoAb 3 also had lower bST concentrations compared with control cows but only from wk 15 to 24 of lactation ( P < 0.05). No correlation was observed between FCM and bST concentrations ( P > 0.05).
No difference in concentrations of IGF-I was observed in cows immunized with MoAb 1 compared with those of the control cows or cows immunized with other MoAb ( P > 0.05; Figure 2c ). Concentrations of IGF-I in cows immunized with MoAb 4 were decreased compared with those of the control cows from wk 15 to 27 of lactation ( P < 0.05). Cows immunized with bST agonist MoAb 2 had increased concentrations of IGF-I compared with control cows between wk 12 and 18 of lactation ( P < 0.05). There was also a tendency of a positive correlation ( r = 0.25) between bST and IGF-I concentrations ( P < 0.1).
Cows immunized with any MoAb had similar feed intake to control cows (40.3 ± 0.3, 41.6 ± 0.3, 40.7 ± 0.3, 41.7 ± 0.3, and 41.5 ± 0.3 kg/d for cows immunized with MoAb 1, 2, 3, and 4 and control cows, respectively; P > 0.05). All treatments had similar BW throughout lactation ( P > 0.05; data not shown). Two cows were observed to have mild mastitis but remained in the study. Health status was otherwise unaffected by the immunizations.
DISCUSSION
The results obtained in the rat bioassay confirm the observation that the somatogenic properties of bST can be enhanced when associated with certain anti-bST MoAb (5, 6, 21, 39, 40, 41) . The MoAbmediated potentiation of ST activity is observed not only for growth but also with increases in serum IGF-I concentrations, liver IGF-I peptide, and mRNA concentrations, which supports an effect of the anti-ST MoAb on ST action at the level of hepatic IGF-I gene expression (25, 28) . The anti-ST MoAb-ST complexes also increase liver somatogenic and lactogenic receptor occupancy (2, 25, 36) . Anti-ovine ST MoAb-ST complexes, which enhance the somatogenic actions of ST, were shown to enhance the lactogenic activity of ST in lactating ewes (29) . Another study, interestingly, showed that anti-rat ST alone was capable of decreasing milk yield by 20% in rats ( 1 8 ) with decreased serum IGF-I concentrations. Therefore, anti-ST was shown to modulate galactopoietic response in vivo.
In the present study, some anti-bST MoAb inhibited the growth-promoting activity of bST, which is more typical of hormone-antibody interactions ( 2 ) . This report is the first of anti-bST MoAb acting as antagonists when complexed with bST in hypophysectomized rats. The mechanisms by which anti-bST MoAb affect somatotrophic activity has been investigated. One hypothesis is a conformational change occurs when the hormone is complexed with the antibST, which leads to restriction of ST binding to certain receptor subtypes or to prevention of internalization or degradation of the ST-receptor complexes, and results in prolonged receptor occupancy and agonistic effects (25) . Circulating GHBP also play an important role in controlling the availability of ST to its receptors (11) . Complexes of GHBP bound to circulating ST prevented ST from interacting with its cellular receptors (11, 12, 16, 24) . High affinity GHBP represent a circulating fragment of the ST receptor, encompassing its extracellular domain. However, the ST receptors have 5 to 10 times higher affinity for ST than GHBP (9, 10). Complexed anti-ST MoAb and ST might preferentially target ST receptors in tissues rather than binding GHBP in the circulation, resulting in enhancement of growth (30, 40, 41) . This interaction probably occurs for MoAb 1 and MoAb 2 when used in the hypophysectomized rat study. In the present study two other anti-bST MoAb (MoAb 3 and 4 ) were able to inhibit growth when complexed with ST. These complexes may bind epitopes at the receptor-binding region of bST and prevent exposure and binding to the receptors. Clearly, these MoAb differ in their epitope specificity, and we decided to use two MoAb of each category to induce anti-idiotypic antibodies in lactating cows. Although there was a tendency for differences in avidity, results based on biological potency showed that the two MoAb within each category could be very similar in terms of epitope specificity.
In a previous study ( 3 3 ) of immunization of lactating cows with rabbit polyclonal anti-bST-induced bST anti-idiotypes, titers increased transiently between repeated immunizations but had no effect on milk yield. In contrast, in the present study immunization of lactating cows with mouse anti-bST MoAb resulted in a rapid and sustained increase in anti-idiotypic titers during the series of immunizations and, for two of the four MoAb, modified milk yield. Use of a mouse MoAb rather than rabbit polyclonal antibodies as antigen, therefore, not only increased the specificity but also the magnitude of immune response. In this context, the MoAb appear to behave as a typical antigen and not to invoke secondary anti-anti-idiotypic responses, consistent with the network theory of Jerne (22) . Because the MoAb were observed to have either agonist or antagonist effects on hypophysectomized rat growth, the array of antibodies with opposing biological activity within a polyclonal mixture would probably yield a mixed response of antiagonists and anti-antagonists and so neutralize the opportunity for the predicted biological effect (33) .
A previous study in our dairy center with the same herd showed a 10% increase in milk and 3.5% FCM production in response to exogenous bST ( 4 2 ) and showed that these cows were in a well-managed environment capable of a positive response to bST.
Immunization with MoAb 1, which was a bSTagonist in the rat bioassay, induced anti-idiotype with a clear antagonistic effect and decreased milk yield by 14% compared with that of controls. This decrease in milk yield was observed from the 6th wk until the end of lactation, coincident with elevated titers of bST anti-idiotypes equivalent to approximately 10-fold the concentration of bST in controls. This MoAb also had the highest avidity for bST (avidity index: 2.8). In contrast, immunization with MoAb 4, a bST antagonist in the rat bioassay, induced anti-idiotype with some bST mimicry by increasing milk yield 13% during peak lactation compared with controls. In this treatment, although the concentrations of bST antiidiotypes were elevated from wk 3 to 30 of lactation, increased milk yield was only observed during wk 3 to 6 and 18 to 21. The MoAb 4 also had the lowest bST avidity index compared with the other three MoAb and the lowest titers of bST anti-idiotypes. Although no correlation was observed between total FCM and MoAb avidity index, this result could be explained by the small number of animals per treated group. When a polyclonal anti-bST was used as antigen in lactating cows (33) , there was a tendency for milk yield to be depressed at the end of lactation when anti-idiotypic titers were highest, which may suggest that antibodies similar to MoAb 1 in the polyclonal anti-bST pool were becoming dominant at this stage (33) .
Although immunization with MoAb 2 and 3 also elevated concentrations of bST anti-idiotypes, milk yield was not affected during any immunization period despite the similarity of these antibodies to MoAb 1 and 4, respectively, in terms of biological activity and avidity. Perhaps in these cases, the antiidiotypes produced had conformation with no bST-like activity. That MoAb 1, which was the most growth stimulating in the rat bioassay, was the least lactogenic in the cow study could be explained by the antiidiotypes produced from MoAb 1 having a conformational change that inhibited binding to the lactogenic receptors. A previous study showed anti-ST directed against amino acid residues 95 -134, and the Cterminus of ST inhibited somatogenic binding more potently than did lactogenic binding ( 2 ) . Therefore, it is possible that the anti-idiotypes produced from antibST MoAb had preferential binding for the somatogenic versus lactogenic receptors or vice versa according to their conformational change. The biological response of anti-idiotypes differed from MoAb 1 and 4, which suggests that different receptor subtype binding occurred.
There was no crossreaction of any of the monoclonal anti-idiotypic antibodies in the radioimmunoassay using the Parlow antiserum raised in monkey. This observation contrasts with the strong crossreactivity of anti-idiotypic antibodies following immunization with a rabbit polyclonal antibody against bST (33) . Immunoactive serum bST concentrations, determined using the Parlow antiserum, declined as lactation progressed as previously described ( 8 ) . In the anti-bST MoAb-immunized cows, this decline was more apparent, especially for MoAb 1. Such a reduction may be involved in the reduced milk yield of the cows immunized against MoAb 1. There is also, however, the possibility that the anti-MoAb 1 idiotypes bind to bST receptors without their full activation, resulting in inhibition of bST action as reflected by reduced milk yield. Alternatively, these anti-idiotypes may interfere with the binding of ST to GHBP, and, therefore, may modulate the effective distribution of ST in the circulation and into tissues. In fact, GHBP have an identical amino acid sequence to the extracellular portion of ST receptor (11) . However, the ST receptor has higher affinity for ST than for GHBP ( 9 ) . The presence of GHBP in bovine plasma and milk has been shown by Western blotting ( 1 6 ) and immunoassays (13, 15) , but GHBP levels were lower in cattle compared with rodents or humans (10) . Depending on the configuration of the anti-idiotypes, it is possible that the anti-idiotypes are preferentially bound to these GHBP, and are, therefore, prevented from binding to the ST receptors (16) . Alternatively, they cannot bind to GHBP but prevent ST from binding to the ST receptors.
Changes in serum IGF-I did not explain the differences in other measures among treatments. Although there was a tendency for a positive correlation between bST and IGF-I concentrations, there was no correlation observed between IGF-I concentrations and FCM ( P > 0.05). There was no difference in IGF-I concentrations between controls and MoAb 1-immunized cows, despite the lower milk yield of the latter. To add to the paradox, IGF-I concentrations were lowest after immunization with MoAb 4, despite higher milk yields at wk 3, 6, 18, and 21, which was the reverse of our expectations. Differences in IGF-I levels varied according to nutrient balance and the stage of lactation with low concentrations of IGF-I during early lactation being associated with low nutrient balance (26) . In addition, there was a correlation observed between the IGF-I response and milk yield response to bST (14, 23) . However, considerable variation existed between animals in the magnitude of the IGF-I response to bST and explained the differences in milk yield response observed between bSTtreated cows (23) . Therefore, that differences were not observed in IGF-I concentrations in MoAb 1-treated cows with lower milk yield could be due to the just mentioned variables.
In conclusion, a monoclonal antibody (MoAb 1), which showed bST-agonistic effects when complexed with bST in a rat growth model, reduced milk yield when used for immunization in lactating cows. Another monoclonal antibody (MoAb 4), which showed bST-antagonistic effects when complexed with bST, increased milk yield transiently when used for immunization. Although the physiological mechanisms underlying these effects are unknown and likely complex, this study demonstrated that there is potential to alter milk yield in lactating cows with this approach.
